The therapeutic efficacy of a clinical candidate drug PF-04691502, a potent dual PI3K/mTOR inhibitor, was further demonstrated in both cell-based assays and in the xenograft tumor model derived from CSCs. Here, PIK3CA is linked to neoplasm.